An animal model further uncovers the role of mutant BrafV600E during papillary thyroid cancer development

Papillary thyroid carcinomas (PTC) account for 90% of human thyroid cancer cases which represent 1% of all cancer cases. They are likely to develop from papillary thyroid microcarcinomas (PTMC) found in up to 36% of healthy individuals due to rare progression events (0.01%). Although the prognosis of PTCs is excellent, 5% to 10% of tumors display an unfavorable outcome. About 45% of PTCs exhibit activating BRAFV600E mutations. Rats of the inbred BD strains postnatally exposed to the carcinogen N-ethyl-N-nitrosourea developed PTMCs which closely resembled their human counterparts judging from their histology, size, and marginal tendency to progress.

Source: American Journal of Pathology - January 13, 2020 Category: Pathology Authors: Bernd Koelsch, Sarah Theurer, Magdalena Staniszewska, Jacqueline Heupel, Amelie Koch, Svenja Mergener, Franziska Walk, Christine Fischer, Andrea Kutritz, Kurt W. Schmid, Andrea Kindler-R öhrborn Tags: Regular Article Source Type: research